Compare STC & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | STC | RAPP |
|---|---|---|
| Founded | 1893 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 1994 | 2024 |
| Metric | STC | RAPP |
|---|---|---|
| Price | $65.44 | $37.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $81.00 | $48.50 |
| AVG Volume (30 Days) | 136.8K | ★ 270.5K |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | ★ 55.17 | 24.34 |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $2,921,636,000.00 | N/A |
| Revenue This Year | $13.62 | N/A |
| Revenue Next Year | $7.13 | N/A |
| P/E Ratio | $120.16 | ★ N/A |
| Revenue Growth | ★ 17.32 | N/A |
| 52 Week Low | $56.39 | $10.57 |
| 52 Week High | $78.61 | $42.27 |
| Indicator | STC | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 46.55 | 50.67 |
| Support Level | $62.45 | $33.55 |
| Resistance Level | $66.92 | $40.81 |
| Average True Range (ATR) | 1.65 | 2.30 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 51.83 | 54.61 |
Stewart Information Services Corp is a customer-focused, title insurance and real estate services company offering products and services to home buyers and sellers, mortgage lenders and servicers, attorneys, and home builders. It has three operating segments: Title insurance and related services which generates key revenue, includes the functions of searching, examining, closing, and insuring the condition of the title to real property. It also includes home and personal insurance services, Real estate solutions segment supports the real estate mortgage industry by providing appraisal management services, online notarization and closing solutions, credit, and real estate information services, search and valuation services. Corporate and other segment is comprised of parent holding company.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.